A Coumarin–Imidazothiadiazole Derivative, SP11 Abrogates Tumor Growth by Targeting HSP90 and Its Client Proteins
Molecules · 2023
DOI: 10.3390/molecules28135226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Snehal Nirgude und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Bioinformatics and Applied Biotechnology, Electronic City Phase 1, Bangalore 560100, Karnataka, India. Hauptthemen laut MEDLINE: Coumarins, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Science and Technology, Department of Biotechnology, DST-INSPIRE.
Abstract (Originalsprache)
Despite several treatment options for blood cancer, mortality remains high due to relapse and the disease’s aggressive nature. Elevated levels of HSP90, a molecular chaperone essential for protein folding, are associated with poor prognosis in leukemia and lymphoma. HSP90 as a target for chemotherapy has been met with limited success due to toxicity and induction of heat shock. This study tested the activity of an HSP90 inhibitor, SP11, against leukemic cells, mouse lymphoma allograft, and xenograft models. SP11 induced cytotoxicity in vitro in leukemic cell lines and induced cell death via apoptosis, with minimal effect on normal cells. SP11 induced cell death by altering the status of HSP90 client proteins both in vitro and in vivo. SP11 reduced the tumor burden in allograft and xenograft mouse models without apparent toxicity. The half-life of SP11 in the plasma was approximately 2 h. SP11 binding was observed at both the N-terminal and C-terminal domains of HSP90. C-terminal binding was more potent than N-terminal binding of HSP90 in silico and in vitro using isothermal calorimetry. SP11 bioavailability and minimal toxicity in vivo make it a potential candidate to be developed as a novel anticancer agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Bioinformatics and Applied Biotechnology, Electronic City Phase 1, Bangalore 560100, Karnataka, India.
- Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
- Dr. Prabhakar B. Kore Basic Science Research Laboratory Center (Off-Campus), Department of Pharmaceutical Chemistry, KLE College of Pharmacy, Rajajinagar, (A Constituent Unit of KLE Academy of Higher Education; Research…
- Department of Biochemistry, Indian Institute of Science, Bangalore 560012, Karnataka, India.
ORCID-Profile: Snehal Nirgude, Febina Ravindran, Sujeet Kumar, Raghunandan Mahadeva, Subhas S Karki
Förderung
- Department of Science and Technology
- Department of Biotechnology
- DST-INSPIRE
- Vision Group of Science & Technology
Zitieren
APA
Nirgude, S., Shahana M V, Ravindran, F., Kumar, S., Sharma, S., Mahadeva, R., Mhatre, A., Karki, S. S., & Choudhary, B. (2023). A Coumarin–Imidazothiadiazole Derivative, SP11 Abrogates Tumor Growth by Targeting HSP90 and Its Client Proteins. Molecules. https://doi.org/10.3390/molecules28135226
Vancouver
Nirgude S, Shahana M V, Ravindran F, Kumar S, Sharma S, Mahadeva R, et al. A Coumarin–Imidazothiadiazole Derivative, SP11 Abrogates Tumor Growth by Targeting HSP90 and Its Client Proteins. Molecules. 2023. doi:10.3390/molecules28135226
BibTeX
@article{Nirgude2023,
author = {Nirgude, Snehal and Shahana M V and Ravindran, Febina and Kumar, Sujeet and Sharma, Shivangi and Mahadeva, Raghunandan and Mhatre, Anisha and Karki, Subhas S and Choudhary, Bibha},
title = {A Coumarin–Imidazothiadiazole Derivative, SP11 Abrogates Tumor Growth by Targeting HSP90 and Its Client Proteins},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28135226}
}
EUVIMED